Background The combination of bevacizumab (B) and erlotinib (E) has shown promising
clinical outcomes as the first-line treatment of advanced HCC patients. We aimed to evaluate …

Objectives: To investigate the clinical efficacy and tolerability of the combination of
bevacizumab (B) and erlotinib (E) compared to sorafenib (S) as first-line treatment for …

Background The efficacy of bevacizumab combined with erlotinib (B+ E) for the treatment of
advanced hepatocellular carcinoma, especially for sorafenib-refractory patients, has been …

Trial registry Clinicaltrials. gov# NCT01180959. Background Early clinical studies of
bevacizumab and erlotinib in advanced hepatocellular carcinoma (HCC) have a tolerable …

4522 Purpose: HCC is the fifth most common solid tumor worldwide and the incidence is
rising in western countries. Current standard of care for advanced HCC is sorafenib based …

Purpose: To evaluate the combination of erlotinib and bevacizumab in subjects with
hepatocellular carcinoma (HCC) who are not candidates for local therapy. Patients and …

Objective: A phase II study was performed to evaluate the efficacy and tolerability of
bevacizumab and erlotinib in advanced hepatocellular carcinoma (HCC) patients, and to …

4567 Purpose: HCC is the 5th most common solid tumor worldwide and the incidence is
rising in western countries.> 75% of patients (pts) have advanced disease and are ineligible …

Background Sorafenib is the only systemic agent to show statistically significant overall
survival (OS) benefits in advanced HCC. Erlotinib is a direct and reversible EGFR tyrosine …

Purpose The study objective was to determine the proportion of patients with hepatocellular
carcinoma (HCC) treated with the combination of bevacizumab (B) and erlotinib (E) who …